$STE (Steris Plc)

$STE {{ '2016-08-09T11:01:39+0000' | timeago}} • Announcement

$STE posted higher earnings in 1Q17, helped by a 45% increase in revenue compared to 1Q16. Net income was $48.4MM or $0.56 per diluted share compared to $24.3MM or $0.40 per diluted share last year. Revenue was $638.4MM compared to $439.9MMM in 1Q16, driven by growth in all four segments. Adjusted net income was $68.4MM or $0.79 per diluted share.

$BMY {{ '2017-07-24T16:32:02+0000' | timeago}} • Announcement

$BMY said the U.S. Food and Drug Administration (FDA) has expanded the indication for Yervoy (ipilimumab) injection for intravenous use to now include the treatment of unresectable or metastatic melanoma in pediatric patients 12 years of age and older.

$PFE {{ '2017-07-24T15:56:36+0000' | timeago}} • Announcement

$PFE's REFLECTIONS B7391003 study, a comparative, confirmatory safety and efficacy study of PF-06439535 versus Avastin, met its primary objective. PF-06439535 is being developed by $PFE as a potential biosimilar to Avastin. Results demonstrate equivalence in objective response rate in patients with advanced non-squamous non-small cell lung cancer.

$MCK {{ '2017-07-21T16:07:44+0000' | timeago}} • Announcement

Biologics, a unit of healthcare technology firm $MCK, said it will join the limited distribution network of $PBYI to promote the latter’s kinase inhibitor Nerlynx. The formulation is indicated for treatment of adult patients with early-stage HER2 overexpressed/amplified breast cancer.

$REGN {{ '2017-07-21T15:50:38+0000' | timeago}} • Announcement

$REGN and $SNY announced that the European Medicine Agency's Committee for Medicinal Products for Human Use has given a positive opinion for the marketing authorization of Dupixent (dupilumab), recommending its approval in Europe for use in adults with moderate-to-severe atopic dermatitis who are candidates for systemic therapy.

$MRK {{ '2017-07-21T15:21:07+0000' | timeago}} • Announcement

President Donald Trump announced that pharma giants $MRK and $PFE are collaborating with Gorilla Glass manufacturer Corning ($GLW) for manufacturing a new glass (Valor Glass), which is superior and reliable for the delivery of injectable drugs. Corning is planning to initially invest $500MM creating 1,000 jobs at 3 facilities in US.

$ENDP {{ '2017-07-21T14:56:21+0000' | timeago}} • Announcement

$ENDP said it will be ceasing operations and closing its manufacturing and distribution facilities in Huntsville, Alabama. The closure is expected to take place over the next 12 to 18 months. These restructuring actions are expected to reduce $ENDP's workforce by about 875 positions and to result in pre-tax restructuring charges of about $325MM.

$ISRG {{ '2017-07-21T12:26:16+0000' | timeago}} • Infographic

$ISRG Intuitive Surgical, Inc. Earnings AlphaGraphics: Q2 2017 highlights

$ISRG {{ '2017-07-20T20:21:13+0000' | timeago}} • Announcement

In 2Q17, $ISRG's service revenue rose 11% to $142MM while instrument and accessory revenue jumped 17% to $398MM. Intuitive Surgical ended the second quarter with $3.4Bil in cash, cash equivalents, and investments.

$ISRG {{ '2017-07-20T20:16:13+0000' | timeago}} • Announcement

In 2Q17, revenue for $ISRG jumped 13% to $756MM while net income soared 20% to $222MM or $5.77 per diluted share. Non-GAAP net income was $228MM or $5.95 per diluted share, with systems revenue increased by approximately 7% to $216MM.

$BAX {{ '2017-07-18T14:01:55+0000' | timeago}} • Announcement

The BoD of $BAX declared a quarterly dividend of $0.16 per share of its common stock. The dividend is payable on Oct 2, 2017, to stockholders of record as of Sept 1, 2017.

$IDXX {{ '2017-07-18T10:56:31+0000' | timeago}} • Announcement

$IDXX unanimously elected Stuart Essig as a member of the company's BoD, effective July 12, 2017. In connection with Essig's election, the Board also increased its size from 8 to 9 members, effective July 12, 2017. Essig has been the Chairman of Integra LifeSciences Holdings Corp. since 2012.

$PG {{ '2017-07-17T22:15:27+0000' | timeago}} • Announcement

$PG said it continues to execute on bold productivity initiatives and plans to deliver up to $10Bil over the next five fiscal years. The company recently announced a 3% increase to its quarterly dividend, and expects total dividend payments to shareholders of more than $7Bil in FY17.

$BAX {{ '2017-07-17T20:58:53+0000' | timeago}} • Announcement

$BAX appointed Cathy Smith, EVP and CFO of $TGT, to its BoD, bringing the total number of directors serving the company at this time to 13. Smith now also serves on $BAX's Audit Committee.

$KAMN {{ '2017-07-17T14:22:49+0000' | timeago}} • Announcement

Kaman Distribution Group, the distribution segment of $KAMN, named Jeff Ames as VP, GM of its Automation platform, effective July 10, 2017. Prior to joining Kaman, Jeff served as GM at $ETN.

$XRAY {{ '2017-07-14T15:40:42+0000' | timeago}} • Announcement

Dental solutions provider $XRAY declared a quarterly cash dividend of $0.0875 per common share. The corresponding annual rate has increased 12.9% to $0.35 per share from the prior annual rate of $0.31 per share. The dividend is payable on April 13, 2017 to shareholders of record on March 31, 2017.

$PFE {{ '2017-07-13T12:13:49+0000' | timeago}} • Announcement

The FDA has accepted $PFE's filing of supplemental New Drug Application (sNDA) for XELJANZ (tofacitinib citrate), an investigational oral treatment for adult patients with moderately to severely active ulcerative colitis. The FDA has provided an anticipated Prescription Drug User Fee Act action date in March 2018 for the sNDA.

$PFE {{ '2017-07-12T11:41:14+0000' | timeago}} • Announcement

$PFE said the FDA's Oncologic Drug Advisory Committee (ODAC) voted that the results of ALFA-0701 demonstrated a favorable risk benefit profile for Mylotarg on days 1, 4 and 7 added to chemotherapy for patients with newly-diagnosed CD33-positive acute myeloid leukemia (AML).

$PFE {{ '2017-07-11T20:58:23+0000' | timeago}} • Announcement

The US FDA's Oncologic Drug Advisory Committee (ODAC) voted in favor of $PFE's MYLOTARG (gemtuzumab ozogamicin), an antibody-drug conjugate used to treat acute myeloid leukemia. The role of the ODAC is to provide recommendations to the FDA. The FDA decision on whether or not to approve MYLOTARG is anticipated by Sept. 2017.

$BMY {{ '2017-07-10T11:35:22+0000' | timeago}} • Announcement

$BMY said the FDA accepted its supplemental New Drug Application (sNDA) to include an indication for Sprycel (dasatinib) to treat children with Philadelphia chromosome-positive chronic phase chronic myeloid leukemia, as well as a powder for oral suspension formulation of Sprycel.

$ENDP {{ '2017-07-06T17:01:40+0000' | timeago}} • Announcement

Following FDA's June 2017 withdrawal request, $ENDP has decided to voluntarily remove OPANA ER, a painkiller, from the market, to prevent its misuse.  As a result, $ENDP expects to incur a pre-tax impairment charge of approx $20MM in 2Q17. Reported net sales of OPANA ER were $158.9MM for FY16 and $35.7MM for 1Q17.

Recent Transcripts

ISRG (Intuitive Surgical, Inc.)
Thursday, July 20 2017 - 8:30pm
POOL (Pool Corp.)
Thursday, July 20 2017 - 3:00pm
PII (Polaris Industries Inc.)
Thursday, July 20 2017 - 2:00pm
MCK (McKesson Corporation)
Thursday, May 18 2017 - 9:00pm
PTX (Pernix Therapeutics Holdings, Inc.)
Monday, May 15 2017 - 8:30pm
ACAD (ACADIA Pharmaceuticals Inc.)
Tuesday, May 9 2017 - 9:00pm
OPK (Opko Health, Inc.)
Tuesday, May 9 2017 - 8:30pm
STE (Steris Plc)
Tuesday, May 9 2017 - 2:00pm
XRAY (DENTSPLY International Inc.)
Tuesday, May 9 2017 - 12:30pm
ENDP (Endo International plc)
Tuesday, May 9 2017 - 12:30pm
IVC (Invacare Corporation)
Tuesday, May 9 2017 - 12:30pm
SNN (Smith & Nephew plc)
Friday, May 5 2017 - 7:30pm
MTD (Mettler-Toledo International Inc.)
Thursday, May 4 2017 - 9:00pm
SRCL (Stericycle, Inc.)
Thursday, May 4 2017 - 9:00pm
KAMN (Kaman Corporation)
Thursday, May 4 2017 - 12:30pm
REGN (Regeneron Pharmaceuticals, Inc.)
Thursday, May 4 2017 - 12:30pm
MTD (Mettler-Toledo International Inc.)
Thursday, May 4 2017 - 12:00pm
MASI (Masimo Corporation)
Wednesday, May 3 2017 - 8:30pm
CLX (The Clorox Company)
Wednesday, May 3 2017 - 5:30pm
PFE (Pfizer Inc.)
Tuesday, May 2 2017 - 2:00pm

AlphaGraphics you may like